• Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)
• Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissue
• Arch continues to perform a Phase II trial for LSALT peptide targeting cardiac surgery-associated-AKI
• Drug toxins and CS-AKI account for up to 50% of all AKI occurring in hospitals, for which there is no treatment available

TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the ...

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement disclosed in a press release July 29, 2024 (the “Offering”). Pursuant to the Offering, Arch issued 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for net proceeds of $600,000 CAD. The proceeds of the Offering will be used by Arch as general working capital and certain research expenses that are not covered by the Company’s existing funding ...

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”).
The proceeds of the Offering will be used by Arch as general working capital and certain research expenses that are not covered by the Company’s existing funding grants. The Offering is expected to close on or before July 31, ...